Oncologianova GmbH Gesellschaft fuer Innovationen in der Onkologie
- Address
- Am Stadion 9, Hillerheide, 45659 Recklinghausen, Germany
Oncologianova GmbH - Advanced Breast Cancer Research Center
Oncologianova GmbH is a specialized clinical research organization dedicated to advancing innovative oncology treatments, with a primary focus on breast cancer therapeutics. The center demonstrates extensive expertise in conducting complex Phase III trials that evaluate novel treatment strategies for various breast cancer subtypes, particularly in neoadjuvant and adjuvant settings.
- Triple-negative breast cancer (TNBC) immunotherapy combining atezolizumab with chemotherapy regimens
- BRCA-mutated breast cancer studies utilizing PARP inhibitors like olaparib as adjuvant therapy
- HER2-negative breast cancer research including antibody-drug conjugates and CDK4/6 inhibitors
- Personalized medicine approaches comparing endocrine therapy combinations versus standard chemotherapy in hormone receptor-positive disease
The organization's research portfolio emphasizes precision oncology and biomarker-driven treatment selection, focusing on improving invasive disease-free survival and reducing relapse risk in high-risk patient populations. Their trials consistently evaluate cutting-edge therapeutic agents including targeted therapies, immunotherapies, and innovative combination strategies designed to optimize outcomes for patients with early-stage breast cancer across different molecular subtypes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oncologianova GmbH Gesellschaft fuer Innovationen in der Onkologie
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Dynamic Marker-Adjusted Personalized Therapy: Ribociclib Plus Endocrine Therapy Versus Chemotherapy in HR+/HER2- Early Breast Cancer | WSG Westdeutsche Studiengruppe GmbH | Phase III | Not Recruiting | Jul 2019 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 2 | Unknown | 2018-06-13 | 2020-10-23 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.